Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
4 studies found for:    11986207 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia
Condition: Leukemia
Intervention: Biological: alemtuzumab
2 Suspended Cyclosporine Plus Methotrexate or Alemtuzumab
Condition: Unrecognized Condition: Mature B or T-cell Neoplasm
Interventions: Drug: Cyclosporine + METHOTREXATE;   Drug: Cyclosporine + CAMPATH-1H
3 Completed A Phase I Extension Trial of Repeated Infusions of ISF35
Condition: Chronic Lymphocytic Leukemia
Intervention: Biological: ISF35
4 Completed A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)
Condition: Chronic Lymphocytic Leukemia
Intervention: Biological: ISF35

Study has passed its completion date and status has not been verified in more than two years.